Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|103|2|349-349

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.103, Iss.2, 2018-02, pp. : 349-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 169-174

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 5, 2014-11 ,pp. : 542-548

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 5, 2013-05 ,pp. : 402-408

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 141-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 210-216

John Wiley & Sons Inc

Access to resources Recommend Favorite